Seeing Is Believing
Currently out of the existing stock ratings of Steve Chesney, 20 are a BUY (43.48%), 6 are a SELL (13.04%), 20 are a HOLD (43.48%).
Analyst Steve Chesney, carries an average stock price target met ratio of 59.54% that have a potential upside of 25.23% achieved within 384 days. Previously, Steve Chesney worked at ATLANTIC EQUITIES.
Steve Chesney’s has documented 91 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 06-Feb-2024.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 12/1/2022. The price target of $295 was fulfilled within 4 days with a profit of $6.85 (2.27%) receiving and performance score of 5.67.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$169
$39.21 (30.21%)
$207
24 days ago
(07-May-2025)
23/35 (65.71%)
$51.79 (44.19%)
130
Hold
$175
$45.21 (34.83%)
$210
26 days ago
(05-May-2025)
1/4 (25%)
$53.2 (43.68%)
26
Buy
$205
$75.21 (57.95%)
$225
29 days ago
(02-May-2025)
39/66 (59.09%)
$81.47 (65.95%)
121
Buy
$255
$125.21 (96.47%)
$300
29 days ago
(02-May-2025)
21/30 (70%)
$131.47 (106.43%)
200
Buy
$187
$57.21 (44.08%)
$300
29 days ago
(02-May-2025)
9/21 (42.86%)
$63.47 (51.38%)
260
What Year was the first public recommendation made by Steve Chesney?